How Cancer Works

Every time a cell divides, it must copy all three billion letters of its DNA code—a process that occasionally introduces typos called mutations. Most mutations are harmless or quickly repaired by the cell's proofreading machinery, but some damage critical genes that control cell division. Environmental factors like tobacco smoke, ultraviolet radiation, certain viruses, and industrial chemicals dramatically increase mutation rates by directly attacking DNA's chemical structure.

Cancer typically requires multiple mutations accumulating over time, which explains why the disease becomes more common with age. A single genetic error rarely causes cancer; instead, cells must acquire a specific combination of mutations that disable several protective systems simultaneously. Some people inherit mutations from their parents—such as BRCA1 or BRCA2 gene defects—which gives them a head start toward cancer, requiring fewer additional mutations to trigger the disease.

The genes most often damaged in cancer fall into two categories: oncogenes and tumor suppressors. Oncogenes are like a cell's accelerator pedal—when mutated, they become stuck in the "on" position, constantly telling the cell to grow and divide. Tumor suppressors act as brake pedals; when these genes are damaged or deleted, the cell loses its ability to stop dividing when appropriate.

Healthy cells respond to dozens of chemical signals from their environment that tell them whether to divide, rest, or die. These signals work through receptors on the cell surface that connect to intricate molecular pathways inside the cell, ultimately reaching the nucleus where genes are turned on or off. Cancer cells accumulate mutations that sever these communication lines, making them deaf to the "stop growing" messages that normally prevent overcrowding and maintain tissue architecture.

A critical checkpoint occurs before cell division, where proteins examine the cell for damage and adequate resources. The p53 protein, often called the "guardian of the genome," normally blocks division if it detects DNA damage, giving the cell time to repair itself or triggering self-destruction if the damage is too severe. More than half of all cancers have disabled p53 through mutation, effectively removing this crucial quality control step.

Cancer cells also generate their own growth signals, creating a self-sustaining loop that no longer depends on instructions from surrounding tissue. They overproduce growth factor receptors or manufacture their own growth factors, stimulating themselves in a process called autocrine signaling. This independence allows cancer cells to thrive in locations where normal cells would remain dormant or die from lack of appropriate signals.

Every normal cell contains a self-destruct mechanism called apoptosis—a programmed cell death sequence that activates when the cell is damaged, infected, or no longer needed. During apoptosis, the cell systematically dismantles itself from within, fragmenting its DNA, breaking down its internal structures, and packaging itself into tidy parcels that neighboring cells can safely consume. This process protects the organism by eliminating cells that might become dangerous; a healthy human kills off about 50 billion cells daily through apoptosis.

Cancer cells disable apoptosis through multiple strategies, allowing them to persist despite accumulating lethal amounts of damage. Many amplify anti-apoptotic proteins like BCL-2, which blocks the release of cytochrome c from mitochondria—a critical early step in the death cascade. Others mutate the p53 gene, which normally detects cellular stress and initiates apoptosis; without functional p53, even severely damaged cells continue dividing indefinitely.

This escape from death becomes particularly problematic during cancer treatment. Chemotherapy and radiation work primarily by damaging cancer cells so severely that they should trigger their own apoptosis. Cancer cells that have disabled this suicide machinery can survive treatments that would kill normal cells, leading to drug resistance and disease recurrence.

Healthy tissues maintain distinct boundaries, with cells held in place by an extracellular matrix—a mesh of proteins and carbohydrates that functions like biological scaffolding. Cells attach to this matrix through adhesion molecules, particularly E-cadherin proteins that act as molecular Velcro, binding cells tightly to their neighbors. Normal cells receive essential survival signals from these attachments; when detached, they typically activate apoptosis in a process called anoikis, preventing cells from wandering to inappropriate locations.

Cancer cells override these constraints by reducing or eliminating E-cadherin expression, weakening the bonds that anchor them in place. They simultaneously increase production of enzymes called matrix metalloproteinases that digest the extracellular matrix, carving tunnels through the tissue barriers. This combination allows cancer cells to detach from the primary tumor and push into surrounding tissue, destroying normal architecture as they advance.

Invasive cancer cells also undergo a transformation called epithelial-mesenchymal transition, where they shed their epithelial characteristics and adopt properties of mesenchymal cells—mobile cells normally involved in wound healing and embryonic development. This shift gives cancer cells the ability to migrate through tissues, squeeze through tight spaces, and resist the apoptosis signal that would normally kill detached cells.

Metastasis—the spread of cancer to distant body sites—causes approximately 90% of cancer deaths, transforming a localized problem into a systemic disease. For cancer cells to metastasize, they must complete an improbable journey: escape the primary tumor, survive in the bloodstream or lymphatic system, exit the circulation at a distant site, and establish a new colony in foreign tissue. Each step presents lethal challenges, yet some cancer cells acquire the precise combination of traits needed to succeed.

Cancer cells enter the bloodstream by inducing angiogenesis—the formation of new blood vessels—around the tumor. These hastily constructed vessels have leaky walls that cancer cells can penetrate relatively easily. Once in circulation, cancer cells face severe mechanical stress from fluid shear forces and attacks from immune cells; fewer than 0.01% survive. Some cancer cells increase their odds by traveling in clusters or coating themselves with platelets, which provide physical protection and help them lodge in distant capillaries.

The location where cancer spreads is not random. Different cancers show distinct patterns of metastasis: breast cancer commonly spreads to bone, liver, and brain, while colon cancer favors the liver. This "organ tropism" reflects both mechanical factors—where circulating cells physically get trapped—and molecular compatibility between cancer cells and specific organs. Cancer cells possess surface proteins that recognize and bind to certain tissues, while those tissues secrete chemical signals that either welcome or repel different cancer types.

Even after arriving at a distant site, cancer cells face a hostile environment chemically different from their tissue of origin. Most enter dormancy, sometimes for years or decades, until acquiring additional mutations or until changes in the local environment—such as inflammation or tissue injury—provide signals that trigger renewed growth. This explains why cancer can recur many years after apparently successful treatment of the original tumor.